2 results
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2024-513392-40-01 check the CTIS register for the current data. The design will be a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to…
Approved WMOPending
The main aim is to test whether cetuximab-IRDye800CW is a reliable marker for residual tumor remnants in resection margins after surgical removal of head and neck cancer. To increase the specificity of cetuximab-800CW, a specific frozen section can…